{
    "clinical_study": {
        "@rank": "109483", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die. Giving drugs in different forms may kill more tumor cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of doxorubicin in treating women with\n      advanced metastatic breast cancer."
        }, 
        "brief_title": "Doxorubicin in Treating Women With Advanced Breast Cancer", 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Determine the antitumor activity of doxorubicin-HPMA conjugate (PK1) in women\n      with advanced breast cancer.\n\n      OUTLINE: This is an open label, multicenter study. Patients receive doxorubicin-HPMA\n      conjugate (PK1) by intravenous infusion once every 3 weeks. Patients may receive a total of\n      6 courses of treatment in the absence of toxicity and progressive disease.\n\n      PROJECTED ACCRUAL: 14-25 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Histologically or cytologically proven advanced metastatic\n        carcinoma of the breast Bidimensionally measurable disease No brain or leptomeningeal\n        disease\n\n        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: WHO 0-2 Life expectancy: At\n        least 3 months Hematopoietic: Hemoglobin at least 10 g/dL Neutrophil count at least\n        2,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 11.7\n        mg/dL AST/ALT no greater than 2 times upper limit of normal (5 times upper limit of normal\n        in presence of liver metastases) Renal: Creatinine no greater than 1.7 mg/dL\n        Cardiovascular: No concurrent treatment for congestive cardiac failure Cardiac function\n        within normal limits by MUGA or ECHO scan, if prior anthracycline therapy Other: Not\n        pregnant or nursing Fertile patients must use effective contraception No concurrent\n        nonmalignant systemic disease No active uncontrolled infection No prior history of\n        malignant disease except: Squamous cell carcinoma of the skin Curatively treated carcinoma\n        in situ of the cervix\n\n        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunological therapy\n        Chemotherapy: At least 1 prior chemotherapy regimen for advanced disease (including\n        adjuvant therapy), but not more than 2 prior regimens At least 4 weeks since prior\n        chemotherapy (6 weeks for nitrosourea or mitomycin) and recovered Cumulative dose of prior\n        epirubicin no greater than 450 mg/m2 Cumulative dose of prior doxorubicin no greater than\n        240 mg/m2 No concurrent chemotherapy Endocrine therapy: No concurrent hormonal therapy Low\n        dose steroid therapy allowed if dose established at least 4 weeks prior to study\n        Radiotherapy: At least 4 weeks since prior radiotherapy and recovered Surgery: Not\n        specified Other: No concurrent experimental therapy"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003165", 
            "org_study_id": "CDR0000065966", 
            "secondary_id": [
                "CRC-PHASE-II-PH2/038", 
                "EU-97028"
            ]
        }, 
        "intervention": {
            "intervention_name": "doxorubicin-HPMA conjugate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Doxorubicin"
        }, 
        "keyword": [
            "stage IV breast cancer", 
            "recurrent breast cancer"
        ], 
        "lastchanged_date": "December 18, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United Kingdom", 
                        "state": "England", 
                        "zip": "B15 2TT"
                    }, 
                    "name": "Cancer Research Campaign Clinical Trials Unit-Birmingham (CRCTU)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newcastle Upon Tyne", 
                        "country": "United Kingdom", 
                        "state": "England", 
                        "zip": "NE4 6BE"
                    }, 
                    "name": "Newcastle General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sheffield", 
                        "country": "United Kingdom", 
                        "state": "England", 
                        "zip": "S1O 2SJ"
                    }, 
                    "name": "Weston Park Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aberdeen", 
                        "country": "United Kingdom", 
                        "state": "Scotland", 
                        "zip": "AB25 2ZN"
                    }, 
                    "name": "Aberdeen Royal Infirmary"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edinburgh", 
                        "country": "United Kingdom", 
                        "state": "Scotland", 
                        "zip": "EH4 9NQ"
                    }, 
                    "name": "Western General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Glasgow", 
                        "country": "United Kingdom", 
                        "state": "Scotland", 
                        "zip": "G11 6NT"
                    }, 
                    "name": "Beatson Oncology Centre"
                }
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "official_title": "A Phase II Trial of PK1 in Women With Advanced Breast Cancer", 
        "overall_official": {
            "affiliation": "University of Glasgow", 
            "last_name": "Chris Twelves, MD, BMedSci, FRCP", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003165"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Glasgow", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 1997", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2010"
    }, 
    "geocoordinates": {
        "Aberdeen Royal Infirmary": "57.15 -2.094", 
        "Beatson Oncology Centre": "55.864 -4.252", 
        "Cancer Research Campaign Clinical Trials Unit-Birmingham (CRCTU)": "52.486 -1.89", 
        "Newcastle General Hospital": "54.978 -1.618", 
        "Western General Hospital": "55.953 -3.188", 
        "Weston Park Hospital": "53.381 -1.47"
    }
}